Companies · Other Health Care

Organicare Nature's Science, LLC

AUSTIN · Other Health Care

Diligence memoA one-page analyst read on Organicare Nature's Science, LLC — recommendation, valuation, rhythm, risks.
$18.1M
Total raised · real
3
Rounds
0.6×
Latest step-up
Top 18%
Sector rank · raised
Series A
Latest stage · inferred · Fri Nov 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Organicare Nature's Science, LLC looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.17× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.
  • Within the normal band (117% of peer median) for its niche.
At-risk
  • Last raise 3.6 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Organicare Nature's Science, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
6.9 yr record
Peak capital year was 2021 with $15.5M across 2 filings.
Market position
ahead of 83% of Other Health Care peers
Capital scale is ahead of 83% of Other Health Care peers; modeled value is above 65% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2021: $15.5M across 2 filings.
  • Largest single filing was $8.5M on 2021-03-30.
  • Filing rows sum to $25.1M, while canonical raised total is $18.1M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Organicare Nature's Science, LLC is one of 5377 Other Health Care companies tracked from AUSTIN. By capital raised it ranks in the upper tier (ahead of 83% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2019-07-31 Raised $4.5M (real) Modeled valuation $92M (est)$4.5M$92MSeries A2019Series A · 2021-02-03 Raised $7.0M (real) Modeled valuation $114M (est)$7.0M$114MSeries A2021Series A · 2021-03-30 Raised $8.5M (real) Modeled valuation $131M (est)$8.5M$131MSeries A2021Series A · 2022-11-18 Raised $5.0M (real) Modeled valuation $43M (est)$5.0M$43MSeries A2022+$7.0M+$8.5M+$5.0MCumulative $25M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.5M · 2019
Series A extension$7.0M · 2021
Series A extension$8.5M · 2021
Series A extension$5.0M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$43.0M
Base estimate est.
$6.4M
Conservative case
$135.0M
Upside case
$22.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $91.8M · 2019-07-312019Series A · modeled $114.2M · 2021-02-03Series A · modeled $131.4M · 2021-03-30Series A · modeled $43.0M · 2022-11-182022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
3.6 yr
Elapsed time used
3.6 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$5.5M/yr
Capital velocity
6.9 yr
On record since
2019
First round
4
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.4× above median
This company$18.1M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.9× of median
This company$5.0M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 1.9× above median
This company$43.0M
Sector median$22.1M

Raised more than 83% of sector peers (real $). Modeled value above 65% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #79 of 196.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)CareHarmony, Inc. · Series A Raised $17.4M · modeled $145.2M (est)Dragonfly Endoscopy Inc. · Series A Raised $12.7M · modeled $142.0M (est)NuvoAir Holdings, Inc. · Series A Raised $10.7M · modeled $125.1M (est)Post Acute Recovery, Inc. · Series A Raised $14.5M · modeled $123.0M (est)Micro Interventional Devices, Inc. · Series A Raised $14.0M · modeled $119.0M (est)Etiometry Inc. · Series A Raised $15.6M · modeled $114.7M (est)SafKan, Inc. · Series A Raised $13.0M · modeled $108.5M (est)BehaVR Holdings, Inc. · Series A Raised $12.1M · modeled $102.1M (est)Outliers Inc. · Series A Raised $13.6M · modeled $101.7M (est)RevMedica, Inc. · Series A Raised $14.2M · modeled $101.2M (est)Innovoyce LLC · Series A Raised $9.9M · modeled $97.6M (est)Prixz, Inc. · Series A Raised $9.2M · modeled $97.4M (est)Organicare Nature's Science, LLC (this company) Raised $18.1M · modeled $43.0M (est)Organicare Nature's Science, LLC
CompanyStageRaised · realValue · estvs peer med.
CareHarmony, Inc.Series A$17.4M$145.2M3.96×
Dragonfly Endoscopy Inc.Series A$12.7M$142.0M3.87×
NuvoAir Holdings, Inc.Series A$10.7M$125.1M3.41×
Post Acute Recovery, Inc.Series A$14.5M$123.0M3.35×
Micro Interventional Devices, Inc.Series A$14.0M$119.0M3.25×
Etiometry Inc.Series A$15.6M$114.7M3.13×
SafKan, Inc.Series A$13.0M$108.5M2.96×
BehaVR Holdings, Inc.Series A$12.1M$102.1M2.78×
Outliers Inc.Series A$13.6M$101.7M2.77×
RevMedica, Inc.Series A$14.2M$101.2M2.76×
Innovoyce LLCSeries A$9.9M$97.6M2.66×
Prixz, Inc.Series A$9.2M$97.4M2.66×
Organicare Nature's Science, LLC this companySeries A$18.1M$43.0M1.17×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.5M2019-07-31$20.7M$91.8M90%
Series A$7.0M2021-02-03$31.8M$114.2M90%
Series A$8.5M2021-03-30$38.6M$131.4M90%
Series A$5.0M2022-11-18$22.7M$43.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.5M2019-07-31
    • First recorded raise — entered as Series A.
    • 25 investors on this round.
  2. Series A$7.0M2021-02-03
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
  3. Series A$8.5M2021-03-30
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Series A$5.0M2022-11-18
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
Intelligence
2023 ~Q4
Modeled next raise · ~13mo cadence
$5.0M
Modeled next size est.range $5.0M$8.0M
0.6×
Last step-up
$5.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Anne David Smalling2022-11
Caroline Goodner2019-07
Cole David Arledge2022-11
Franco David Papa2021-02
Franco Talbot Papa2019-07
H. David Shockley, Jr.2019-07
Joe David Aragona2022-11
Jonathan Talbot Brickley2019-07
Rene David Van De Zande2021-02
Registry & provenance

Organicare Nature's Science, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1784348
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Perthera, Inc.Other Health CareSeries A$17.9M$49.3Msame sector · same stage
2GHealth Inc.Other Health CareSeries A$17.5M$35.7Msame sector · same stage
Kinnos Inc.Other Health CareSeries A$17.3M$39.1Msame sector · same stage
Phraxis Inc.Other Health CareSeries A$19.0M$39.6Msame sector · same stage
CorneaGen Inc.Other Health CareSeries A$17.0M$40.4Msame sector · same stage
NextGen Jane, Inc.Other Health CareSeries A$19.5M$44.7Msame sector · same stage
Vertical Orthopaedics, Inc.Other Health CareSeries A$16.7M$44.0Msame sector · same stage
Trumpet Search, LLCOther Health CareSeries A$16.6M$50.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Botany Scientifics LLCOther Health CarePre-Seed$1.4M86%
Nature's Care & Wellness, LLCHealthtechPre-Seed$29.0M85%
Organic Conceptions, Inc.Agtech / FoodtechPre-Seed$4.3M84%
In Vitro Sciences, LLCOther Health CareSeries B$697.9M83%
Natural Partners, IncOther Health CareSeries B$553.9M83%
National Green Biomed Ltd.Other Health CarePre-Seed$3.3M82%
Organic Remedies MO, Inc.Agtech / FoodtechSeed$11.6M82%
Nature's Care & Wellness of Ohio, LLCHealthtechPre-Seed$10.0M82%
Frequently asked
How much funding has Organicare Nature's Science, LLC raised?
Organicare Nature's Science, LLC has raised approximately $18.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Organicare Nature's Science, LLC's estimated valuation?
Provath's modeled valuation for Organicare Nature's Science, LLC is approximately $43.0M (modeled range $6.4M–$135.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Organicare Nature's Science, LLC at?
Organicare Nature's Science, LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Nov 18.
What does Organicare Nature's Science, LLC do and where is it based?
Organicare Nature's Science, LLC operates in the Other Health Care sector, based in AUSTIN.
Explore related

See where Organicare Nature's Science, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Organicare Nature's Science, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.